[The immediate results of the use of isometronidazole in the combination therapy of patients with lung cancer].
The paper is devoted to assessment of isometronidazole tolerance, used as a radiosensitizer for preoperative irradiation of lung cancer patients, and to characterization of morphological postradiation changes in tissues of carcinomas removed at operation. Isometronidazole was shown to cause no severe side-effects in patients, improving considerably radiation injury of the tumor parenchyma.
Zharkov
V V
VV
Merkle
K Kh
KKh
Gentshel
M
M
Furmanchuk
A V
AV
Kurchin
V P
VP
Demidchik
Iu E
IuE
Moiseev
P I
PI
D000328:Adult; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery; D008297:Male; D008795:Metronidazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*
D011838:Radiation-Sensitizing Agents; D008795:Metronidazole; C031624:isometronidazole
Neposredstvennye rezul'taty primeneniia izometronidazola pri kombinirovannom lechenii bol'nykh rakom legkogo.